Study of a new drug for diabetic macular edema
Part of Eyes & vision, Hormones & metabolism clinical trials.
This trial tests a new medication, CU06-1004, for people with diabetic macular edema, a condition that causes blurry vision due to fluid buildup in the central part of the retina. The goal is to see if this drug can reduce the swelling and improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have type 1 or type 2 diabetes.
- Your macular edema involves the center of the retina and is due to diabetes.
- Your vision in the study eye is between 20/50 and 20/320 (moderate to severe vision loss).
- You have not had certain eye treatments recently (e.g., anti-VEGF injections within the last 3-6 months, steroids within the last 12 months, or laser treatment within the last 3 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medication that may reduce swelling in the retina caused by diabetes. If you have diabetic macular edema affecting your central vision, this trial could help you preserve or improve your sight.
This Phase 1 study tests the safety and early effectiveness of OCU200 eye injections in people with diabetic macular edema (DME) that affects the center of vision. It may help by reducing the eye swelling that blurs vision from diabetes.
This study tests different doses of a new medicine (BI 3812465) injected into the eye to treat diabetic macular edema—swelling in the back of the eye caused by diabetes that can blur vision. The trial measures how safe the medicine is and how well patients tolerate it.
This study tests a treatment for diabetic macular edema (swelling in the back of the eye caused by diabetes) in people who have not had eye injections before. It aims to see if the treatment can improve vision.
This study tests a new medicine called SZN-8141 for people with diabetic macular edema (DME), a condition that causes swelling in the back of the eye due to diabetes. The medicine is given as an injection into the eye, and the goal is to reduce swelling and improve vision.
This study compares two injectable medicines (BAT5906 and Lucentis) to treat diabetic macular edema—swelling in the back of the eye that blurs vision. Both drugs block a protein that causes abnormal blood vessel leakage, and this trial will show which works better.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.